According to the results of our in vitro experiments, in order to further verify whether bergenin can reduce oxidative stress and pulmonary fibrosis by activating Nrf2, we used 30 mg/kg of ML385 as a pretreatment and administered it intraperitoneally 3 h before bergenin treatment (Figure 6A). This evidence concerns the gene NFE2L2 and pulmonary fibrosis.